Your browser doesn't support javascript.
loading
Adjunctive continuous theta burst stimulation for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled studies.
Cai, Dong-Bin; Qin, Xiu-De; Qin, Zhen-Juan; Lan, Xian-Jun; Wang, Jian-Jun; Ng, Chee H; Zheng, Wei; Xiang, Yu-Tao.
Afiliación
  • Cai DB; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
  • Qin XD; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
  • Qin ZJ; The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, China.
  • Lan XJ; The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, China.
  • Wang JJ; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
  • Ng CH; Department of Psychiatry, The Melbourne Clinic and St Vincent's Hospital, University of Melbourne, Richmond, Victoria, Australia. Electronic address: cng@unimelb.edu.au.
  • Zheng W; The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China. Electronic address: zhengwei0702@163.com.
  • Xiang YT; Unit of Psychiatry, Department of Public Health and Medicinal Administration, & Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao SAR, China; Centre for Cognitive and Brain Sciences, University of Macau, Macao SAR, China.. Electronic address: xyutly@gmai
J Affect Disord ; 346: 266-272, 2024 02 01.
Article en En | MEDLINE | ID: mdl-37924984
ABSTRACT

OBJECTIVES:

As a novel type of theta burst stimulation (TBS), continuous TBS (cTBS) has been shown to have mixed therapeutic effects for major depressive disorder (MDD) or bipolar depression (BD). Thus, we performed a meta-analysis of randomized controlled trials (RCTs) of cTBS for treating major depressive episodes in patients with MDD or BD.

METHODS:

A systematic search of four major bibliographic databases (PubMed, EMBASE, Cochrane Library, and PsycINFO) was conducted from inception dates to February 3, 2023 to identify eligible studies. The data were analyzed using a random-effects model.

RESULTS:

Three RCTs (n = 78, active cTBS = 37 and sham cTBS = 41) were included the meta-analysis. No significant differences were found in terms of change in Hamilton Depression Rating Scale (HAMD) scores (3 RCTs, n = 78, SMD = -0.09, 95 % CI -0.53 to 0.36; I2 = 0 %; P = 0.71) and study-defined response (2 RCTs, n = 58, 26.7 % versus 21.4 %, RR = 1.20, 95 % CI 0.48 to 2.96; I2 = 0 %; P = 0.70) between active and sham cTBS groups. Similarly, no group differences were found in the rates of adverse events and discontinuation due to any reason (P > 0.05).

LIMITATIONS:

Meta-analysis had small sample sizes and low number of included studies.

CONCLUSIONS:

Although cTBS appeared to be a safe and well-tolerated option for treating major depressive episodes in MDD or BD patients, no advantage in treatment effects was found in this meta-analysis. Future large-scale studies are warranted to assess the efficacy of cTBS for MDD or BD patients with a major depressive episode.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_doencas_nao_transmissiveis Asunto principal: Trastorno Bipolar / Trastorno Depresivo Mayor Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: J Affect Disord Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_doencas_nao_transmissiveis Asunto principal: Trastorno Bipolar / Trastorno Depresivo Mayor Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: J Affect Disord Año: 2024 Tipo del documento: Article País de afiliación: China
...